Stockscreener 앱 받기
7.325
0.48%
0.025
전일 마감가:
$7.30
열려 있는:
$7.28
하루 거래량:
437.52K
Relative Volume:
0.34
시가총액:
$440.20M
수익:
$91.06M
순이익/손실:
$-503.14M
주가수익비율:
-0.8731
EPS:
-8.39
순현금흐름:
$-424.74M
1주 성능:
-5.60%
1개월 성능:
+6.92%
6개월 성능:
+23.48%
1년 성능:
-47.38%
1일 변동 폭
$7.135
$7.36
1주일 범위
$7.135
$7.82
52주 변동 폭
$4.62
$14.31
Sage Therapeutics Inc Stock (SAGE) Company Profile
명칭
Sage Therapeutics Inc
전화
617-299-8380
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
SAGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
7.335 | 440.20M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.98 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.99 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.08 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.20 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.22 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-11 | 재개 | BofA Securities | Underperform |
| 2024-11-21 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-29 | 개시 | Citigroup | Sell |
| 2024-05-29 | 개시 | Robert W. Baird | Neutral |
| 2024-04-17 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-08-08 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-08-08 | 다운그레이드 | Needham | Buy → Hold |
| 2023-08-07 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-08-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-08-07 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-08-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-03-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-03-31 | 개시 | Berenberg | Hold |
| 2021-11-02 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-04-07 | 개시 | Piper Sandler | Overweight |
| 2021-02-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-02-25 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 재개 | Raymond James | Mkt Perform |
| 2021-01-22 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-01-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | 재확인 | H.C. Wainwright | Neutral |
| 2020-09-11 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-08-10 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-04-08 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-03-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-28 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-06 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-12-05 | 재확인 | Guggenheim | Buy |
| 2019-12-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-10-30 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-23 | 개시 | Wedbush | Outperform |
| 2019-04-25 | 개시 | Jefferies | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-11 | 개시 | Oppenheimer | Outperform |
모두보기
Sage Therapeutics Inc 주식(SAGE)의 최신 뉴스
Invesco Ltd. Purchases 4,629 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
What is HC Wainwright’s Forecast for SAGE Q1 Earnings? - Defense World
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call Transcript - Insider Monkey
Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty - TipRanks
Balance Sheet Breakdown: Sage Therapeutics Inc (SAGE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ... - Yahoo Finance
SAGE Reports Q1 Revenue Below Estimates, Highlights ZURZUVAE Gro - GuruFocus
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: S - GuruFocus
Sage Therapeutics Reports Strong Q1 2025 Performance - TipRanks
Sage Therapeutics outlines Q1 2025 growth in ZURZUVAE prescriptions and pipeline progress - MSN
Sage Therapeutics Q1 2025 Earnings: Revenue at $13.8M Misses Est - GuruFocus
Sage Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SAGE) - Seeking Alpha
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast - Investing.com
Sage Therapeutics Announces First Quarter 2025 Financial Results - GuruFocus
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates - BioSpace
SAGE THERAPEUTICS Earnings Results: $SAGE Reports Quarterly Earnings - Nasdaq
What to Expect from Sage Therapeutics's Earnings - Benzinga
Get in on Sage Therapeutics Inc’s (SAGE) buy-in window today! - Sete News
Sage Therapeutics Inc [SAGE] Insider Activity: An Update for Investors - knoxdaily.com
Sage Therapeutics’ (SAGE) “Hold” Rating Reiterated at Needham & Company LLC - Defense World
Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Geode Capital Management LLC Increases Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Russell Investments Group Ltd. Lowers Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - PR Newswire
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Sage Therapeutics (SAGE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Wedbush Research Analysts Raise Earnings Estimates for SAGE - American Banking and Market News
Lobbying Update: $50,000 of SAGE THERAPEUTICS lobbying was just disclosed - Nasdaq
Q1 EPS Estimates for Sage Therapeutics Increased by Wedbush - Defense World
Q1 Earnings Forecast for SAGE Issued By Wedbush - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - markets.businessinsider.com
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 - BioSpace
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 | SAGE Stock News - GuruFocus
Corebridge Financial Inc. Sells 2,050 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Vanguard Group Inc. - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sage Therapeutics Inc (SAGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):